Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Using Real World Data To Assess Safety Of COVID-19 Vaccines

Oxford/AstraZeneca Vaccine Renamed Vaxzevria In The EU

Executive Summary

The EMA is investigating possible links between the three COVID-19 vaccines currently being used in Europe and cases of thrombotic events. It is also planning safety studies in targeted populations.

You may also be interested in...

Coronavirus Notebook: EU Leaders Cool On Vaccine Export Plans, EMA OKs New Production Plants

Sputnik V is to be manufactured by a plant in Serbia, and the UK has set up a new health security agency to deal with emerging future threats.

Europe To Resume AZ Vaccine Use After Safety Review, But Confidence Knocked

The EMA’s conclusions are in line with those of the UK regulator and the World Health Organization, but EU countries’ stop-start decisions will have done nothing to boost the public’s trust in the vaccine.

EU Approves Paxlovid For COVID-19

The European Medicines Agency’s assessment of the oral antiviral combination was conducted under the OPEN Initiative, which involves information sharing among international regulators.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts